ResMed Inc. Faces a Rocky Recovery as Valuation Drops 31 % Amid Market Turmoil

ResMed Inc. (RMD), the San Diego‑based supplier of medical equipment for sleep‑disordered breathing, has plunged 31 % in the past 24 hours, sparking a flurry of analyst commentary and investor debate. The stock’s most recent close, at $208.96 on July 27, 2026, sits just above the 52‑week low of $180.27 and well below the peak of $293.81 recorded on August 21, 2025. With a market capitalization of $29.29 billion and a price‑earnings ratio of 19.55, the company appears overvalued relative to its fundamental earnings, yet undervalued by some value investors who argue the 31 % drop signals a rebound opportunity.

Market Sentiment Turns Negative

The sharp decline was mirrored across the Australian stock exchange, where ASX healthcare stocks, including RMD, experienced a 36 % year‑to‑date loss. Reports from MarketIndex on July 28 and 29 highlighted the broader sector’s pain, noting that even stalwarts such as CSL and Cochlear suffered losses exceeding 50 %. Despite an earlier 4 % rally, the sentiment has flipped, with analysts questioning whether the dip is a temporary wobble or a sign of deeper structural weakness.

Investor Arguments for a Bottom

Contrastingly, several Australian outlets—including The Fool and MarketIndex—have urged investors to consider the current price as the “cheapest valuation in a decade.” The argument rests on ResMed’s core business resilience: its product portfolio remains essential for a growing market of patients with sleep‑disordered breathing, and the company’s global distribution network provides a steady revenue stream. In this view, the 31 % plunge has merely corrected an over‑optimistic rally rather than foreshadowing a prolonged decline.

Macro‑Environment and External Pressures

External factors are also at play. The Australian Reserve Bank’s easing of rate‑hike fears on July 28 lifted the ASX 200 to a six‑week high, yet the healthcare sector lagged, suggesting that broader macro‑economic relief has not yet translated into sector‑specific confidence. Oil price volatility, geopolitical tensions, and commodity market swings have further muddied the waters, diverting investor focus away from cyclical sectors like healthcare.

Conclusion

ResMed Inc. stands at a crossroads. The 31 % drop may represent a fleeting correction or the beginning of a more extended retracement, depending on whether the company can maintain its earnings trajectory and navigate the volatile macro‑economic backdrop. Investors must weigh the compelling narrative of a “bottom” against the unsettling reality of sector‑wide weakness and macro‑economic uncertainty.